Zhao Yanmin, Zhejiang University, etc.: Eltrombopag successfully treats refractory pure red blood cell aplastic anemia after allogeneic hematopoietic stem cell transplantation with ABO blood group incompatibility

Content Introduction Chinese Abstract: Summary: Pure red blood cell aplastic anemia is a common complication after ABO incompatible allogeneic hematopoietic stem cell transplantation
.

There are a variety of methods to treat this complication, including high-dose hormones, erythropoietin, plasma exchange, immunoadsorption, donor lymphocyte infusion, rituximab, bortezomib, daratumumab As well as reducing and stopping immunosuppressive agents
.

In this article, we present a case of pure red blood cell aplastic anemia after ABO incompatible allogeneic hematopoietic stem cell transplantation
.

Recombinant human erythropoietin, glucocorticoids, donor lymphocyte infusion, plasma exchange, and immunosuppressant reduction have no obvious effect on it.
Finally, the patient is treated with a full dose of Eltrombopag and a long course of treatment.
To recover
.

By speculating on the mechanism of Eltrombopag in the treatment of pure red blood cell aplastic anemia, we found that Eltrombopag may be effective for monoline hematopoiesis, and can be used for pure red blood cell regeneration after ABO incompatible allogeneic hematopoietic stem cell transplantation Treatment of obstructive anemia
.

Keyword group: pure red blood cell aplastic anemia; allogeneic hematopoietic stem cell transplantation; Eltrombopag Authors: Yang GAO, Fei GAO, Jimin SHI, Huarui FU, He HUANG, Yanmin ZHAO This text cited format: Yang GAO, Fei GAO, Jimin SHI, Huarui FU, He HUANG, Yanmin ZHAO.
Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation[J].
Journal of Zhejiang University Science B, 2021, 22(8): 695- 700.
http://doi.
org/10.
1631/jzus.
B2000532 The essential guide of this article: Full text download address: http:// B2000532 About this journal "Journal of Zhejiang University (English Edition) Series B: Biomedicine and Biotechnology", referred to as JZUS-B, is a comprehensive English monthly publication of biology
.

JZUS-B since 2008 were included SCI-E, the latest impact factor of 3.
066, while being MEDLINE / PubMed, PMC, Scopus, BA, BIOSIS Previews other well-known platforms retrieval
.

The scope of articles accepted by JZUS-B covers life sciences, medicine, pharmacy, biochemistry, biotechnology and bioengineering, agronomy, ecological environment, and zoology and other related disciplines
.

Article types include Review, Article, Perspective, Viewpoint, Editorial, Correspondence and so on
.

The journal has always implemented a strict international peer review mechanism, with an average review period of 42 days and an average acceptance time of 53 days
.

Articles will be in press online immediately after acceptance, and will generally be officially published within 2 months
.

"Content-oriented, flexible form" is the characteristic of this journal
.

JZUS-B welcomes outstanding scholars at home and abroad to contribute the latest scientific research results, controversial topics, review papers, and organize the publication of hot albums
.

Journal Springer homepage: https:// Online submission address: http:// Contact Us The English version of Zhejiang University News is a number of English academic journals The collection scope covers all directions of science, engineering, agriculture and medicine.
Welcome to contribute to our journal.
You can follow our public account zdxbywb for more information
.